- Home
- TYRA vs UPXI Comparison
TYRA vs UPXI Comparison
Compare TYRA & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- UPXI
- Stock Information
- Founded
- TYRA 2018
- UPXI 2018
- Country
- TYRA United States
- UPXI United States
- Employees
- TYRA N/A
- UPXI N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- TYRA Health Care
- UPXI Health Care
- Exchange
- TYRA Nasdaq
- UPXI Nasdaq
- Market Cap
- TYRA 571.9M
- UPXI 481.8M
- IPO Year
- TYRA 2021
- UPXI 2021
- Fundamental
- Price
- TYRA $12.45
- UPXI $6.63
- Analyst Decision
- TYRA Strong Buy
- UPXI
- Analyst Count
- TYRA 8
- UPXI 0
- Target Price
- TYRA $31.00
- UPXI N/A
- AVG Volume (30 Days)
- TYRA 235.9K
- UPXI 6.0M
- Earning Date
- TYRA 11-06-2025
- UPXI 05-16-2025
- Dividend Yield
- TYRA N/A
- UPXI N/A
- EPS Growth
- TYRA N/A
- UPXI N/A
- EPS
- TYRA N/A
- UPXI N/A
- Revenue
- TYRA N/A
- UPXI $16,562,327.00
- Revenue This Year
- TYRA N/A
- UPXI $299.03
- Revenue Next Year
- TYRA N/A
- UPXI N/A
- P/E Ratio
- TYRA N/A
- UPXI N/A
- Revenue Growth
- TYRA N/A
- UPXI 1378.83
- 52 Week Low
- TYRA $6.42
- UPXI $1.90
- 52 Week High
- TYRA $29.60
- UPXI $22.57
- Technical
- Relative Strength Index (RSI)
- TYRA 58.97
- UPXI 50.95
- Support Level
- TYRA $11.70
- UPXI $5.20
- Resistance Level
- TYRA $12.55
- UPXI $5.99
- Average True Range (ATR)
- TYRA 0.68
- UPXI 0.73
- MACD
- TYRA -0.03
- UPXI -0.16
- Stochastic Oscillator
- TYRA 52.50
- UPXI 36.55
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.